Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC).

Abstract

BACKGROUND/AIMS:

This prospective randomized study was aimed to clarify the efficacy of epirubicin after radical hepatic resection for hepatcellular carcinoma (HCC).

MATERIALS AND METHODS:

One hundred and one patients entered the present study and were randomly allocated to Group A in which UFT (300 mg/day) was given from 5th postoperative week for one year, or Group B in which a bolus injection of epirubicin (40 mg/m2) was given arterially, in addition to the same UFT administration, on day 28. Groups A and B included 40 and 48 eligible cases, respectively.

RESULTS:

No obvious intergroup differences were observed including prescribed dose of UFT. The 1-, 3- and 5-year survival rates (Groups A vs B) were 82 vs 90%, 50 vs 49% and 35 vs 30% (p = 0.2162). Excluding 4 operative deaths, the recurrence-free survival rates were 65 vs 70%, 32 vs 37% and 14 vs 17% (p = 0.3843). Initial recurrence sites were also similar.

CONCLUSIONS:

A bolus arterial injection of epirubicin does not change the long term results after radical hepatic resection for HCC.

• Authors: H Kohno, N Nagasue, T Hayashi, A Yamanoi, M Uchida, T Ono, H Yukaya, N Kimura, T Nakamura
• Journal: Hepato-gastroenterology (Hepatogastroenterology) 1996 Nov-Dec Vol. 43 Issue 12 Pg. 1405-9 ISSN: 0172-6390 [Print] Greece
• PMID: 8975939 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Antibiotics, Antineoplastic
• Drug Combinations
• UFT(R) drug
• Tegafur
• Epirubicin
• Uracil

Topics

• Aged
• Antibiotics, Antineoplastic (therapeutic use)
• Carcinoma, Hepatocellular (drug therapy, surgery)
• Chemotherapy, Adjuvant
• Drug Combinations
• Epirubicin (therapeutic use)
• Female
• Hepatectomy
• Humans
• Liver Neoplasms (drug therapy, surgery)
• Male
• Middle Aged
• Neoplasm Recurrence, Local
• Prospective Studies
• Tegafur (therapeutic use)
• Treatment Outcome
• Uracil (therapeutic use)